证券代码：002900 证券简称：哈三联 公告编号：2025-063 哈尔滨三联药业股份有限公司 第四届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第四届监事会第二 十一次会议于 2025 年 10 月 21 日以电子邮件及微信形式向全体监事发出通知。 2、本次会议于 2025 年 10 月 23 日在公司会议室以现场表决方式召开。 3、本次会议应出席监事 3 人，实际出席会议并表决的监事 3 人。 4、公司监事会主席翟玉平先生主持本次会议。 二、监事会会议审议情况 会议审议通过了以下议案： 1、审议通过《关于 2025 年第三季度报告的议案》 经审核，监事会认为董事会编制和审议公司 2025 年第三季度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决情况：有效表决 3 票，同意 3 票，反对 0 票，弃权 0 票； 表决结果：通过。 2、审议通过 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-062 第四届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第四届董事会第二 十六次会议于 2025 年 10 月 21 日以电子邮件及微信形式向全体董事发出通知。 2、本次会议于 2025 年 10 月 23 日以通讯表决的方式召开。 3、本次会议应出席董事 9 人，实际出席会议并表决的董事 9 人。 哈尔滨三联药业股份有限公司 4、公司董事长秦剑飞先生主持本次会议，公司监事、总裁及董事会秘书列 席会议。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律、 行政法规、部门规章、规范性文件及《哈尔滨三联药业股份有限公司章程》的有 关规定。 二、董事会会议审议情况 会议审议并通过以下议案： 1、审议通过《关于 2025 年第三季度报告的议案》 表决情况：有效表决 9 票，同意 9 票，反对 0 票，弃权 0 票 表决结果：通过 本议案已经第四届董事会审计委员会 2025 年第四次 ...

哈尔滨三联药业股份有限公司 表决结果：通过。 二、审议通过《关于拟参与竞拍资产暨关联交易的议案》 经核查，公司本次拟参与竞拍有助于推动公司产业布局的全面发展，同时充 分发挥业务的协同性，符合公司发展需要，不存在损害公司及全体股东特别是中 小股东利益的情形。会议的表决程序符合《公司法》《证券法》等有关法律法规 和《公司章程》的规定。同意将该议案提交董事会审议。 第四届董事会 2025 年第四次 独立董事专门会议决议的公告 哈尔滨三联药业股份有限公司（以下简称"公司"）第四届董事会 2025 年第 四次独立董事专门会议于 2025 年 10 月 21 日以电子邮件、微信形式向全体独立 董事发出通知，于 2025 年 10 月 21 日以通讯方式召开。会议应出席独立董事 3 人，实际出席的独立董事 3 人。本次会议的通知、召集和召开程序符合法律、法 规及《公司章程》、《独立董事工作制度》的相关规定，会议由独立董事王栋先 生召集并主持，经与会独立董事讨论，形成会议决议如下： 一、审议通过《关于独立董事专门会议豁免提前通知的议案》 全体独立董事一致同意豁免本次会议提前 3 日通知的时限要求，同意于 2025 年 10 ...

Financial Performance - The company's revenue for Q3 2025 was ¥167,526,697.03, a decrease of 46.83% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥116,451,164.25, representing a decline of 913.69% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥121,245,126.35, down 1,113.19% from the previous year[5]. - Total operating revenue for the current period was CNY 580,649,067.87, a decrease of 30.8% compared to CNY 838,525,846.47 in the previous period[19]. - The net profit for the current period was a loss of CNY 211,476,435.44, compared to a profit of CNY 37,498,969.48 in the previous period[19]. - The total comprehensive income amounted to -211,476,435.44 CNY, down from 37,498,969.48 CNY in the prior period[20]. - The basic and diluted earnings per share were both -0.66 CNY, compared to 0.13 CNY in the previous period[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,609,272,790.67, a decrease of 5.03% from the end of the previous year[5]. - Current assets totaled CNY 1,187,835,221.22, down from CNY 1,471,966,906.93, indicating a decrease of 19.3%[16]. - Non-current assets increased to CNY 2,421,437,569.45 from CNY 2,328,501,363.24, representing a growth of 4.0%[17]. - Total liabilities rose to CNY 1,704,282,058.15 from CNY 1,636,313,285.80, an increase of 4.1%[18]. - The total owner's equity decreased to CNY 1,904,990,732.52 from CNY 2,164,154,984.37, a decline of 12.0%[18]. Cash Flow - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥27,645,727.39, up 161.27% year-to-date[5]. - Cash flow from operating activities generated a net inflow of 27,645,727.39 CNY, a recovery from a net outflow of -45,120,146.94 CNY in the prior period[22]. - Cash inflow from investment activities was 144,266,659.10 CNY, down from 225,785,193.74 CNY in the previous period[22]. - Cash outflow from investment activities totaled 316,908,290.76 CNY, compared to 504,051,443.94 CNY in the prior period[22]. - Cash flow from financing activities generated a net inflow of 231,513,898.50 CNY, compared to 304,959,417.97 CNY in the previous period[22]. - The ending cash and cash equivalents balance was 641,999,568.80 CNY, up from 523,931,302.90 CNY in the prior period[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 37,527, with no preferred shareholders[12]. - The largest shareholder, Qin Jianfei, holds 39.10% of shares, totaling 123,705,000 shares, with 21,000,000 shares pledged[13]. Expenses and Income - The company’s financial expenses surged by 3,555.24% to ¥12,782,675.20, primarily due to a decrease in interest income and loan subsidies[9]. - The investment income decreased by 34.75% to ¥16,629,941.00, attributed to reduced earnings from affiliated companies[9]. - The company’s public value change loss was -¥9,770,148.86, reflecting a further decline in the fair value of securities investments[9]. - Credit impairment losses increased by 783.77% to CNY 1,754,410.33 due to a decrease in receivables and the reversal of bad debt provisions[10]. - Asset impairment losses decreased by 4,378.31% to CNY -53,955,391.28, primarily due to significant declines in product prices and large inventory write-downs[10]. - Cash received from government subsidies related to operating activities increased by 55.94% to CNY 87,080,270.16, reflecting higher deferred income from government support[10]. - Cash received from investment income rose by 40.05% to CNY 29,082,226.10, attributed to increased dividends from long-term equity investments[10]. - Cash paid for fixed assets and intangible assets decreased by 43.05% to CNY 146,908,290.76, indicating reduced project investments during the reporting period[10]. - The company reported a significant decrease in other operating expenses, down 95.77% to CNY 58,206.03, compared to the previous year[10]. - The company paid 202,613,824.39 CNY in employee compensation, down from 230,107,253.43 CNY in the prior period[22].

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.32% on October 22, with Dize Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Xiangdi Pharmaceutical (301211) with a closing price of 14.99, up 14.25% [1] - Duorui Pharmaceutical (301075) at 58.62, up 10.21% [1] - Guangji Pharmaceutical (000952) at 7.77, up 10.06% [1] - Hasi Lian (002900) at 14.61, up 10.02% [1] - Yatai Pharmaceutical (002370) at 7.70, up 10.00% [1] - Dize Pharmaceutical (688192) was the biggest loser, closing at 60.11, down 6.20% [2] - Other significant decliners included: - Kangzhiyue Pharmaceutical (300086) down 5.90% [2] - Puluo Pharmaceutical (000739) down 5.41% [2] Capital Flow - The chemical pharmaceutical sector saw a net inflow of 185 million yuan from institutional investors, while retail investors experienced a net inflow of 41.4 million yuan [2] - However, speculative funds recorded a net outflow of 227 million yuan [2] Individual Stock Capital Flow - Notable capital flows for specific stocks included: - Yatai Pharmaceutical (002370) with a net inflow of 2.38 billion yuan from institutional investors, but a net outflow of 95.28 million yuan from speculative funds [3] - Anglikang (002940) had a net inflow of 182 million yuan from institutional investors, with a net outflow of 97.14 million yuan from speculative funds [3] - Hasi Lian (002900) recorded a net inflow of 117 million yuan from institutional investors, but a significant net outflow of 59.36 million yuan from speculative funds [3]

Market Overview - The Shanghai Composite Index is at 3907.95 points, slightly down by 0.21%, and is above the five-day moving average [1] - The total trading volume of A-shares today is 137.8 billion yuan [1] Stocks Performance - A total of 537 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Wanda Bearings with a deviation rate of 9.53% and a daily increase of 12.27% [1] - Electric Wind Power with a deviation rate of 9.42% and a daily increase of 13.35% [1] - Tianwo Technology with a deviation rate of 8.10% and a daily increase of 10.00% [1] Detailed Stock Data - The following stocks have notable performance metrics: - Wanda Bearings (Code: 920002): Latest price 115.99 yuan, five-day moving average 105.89 yuan, daily turnover rate 9.75% [1] - Electric Wind Power (Code: 688660): Latest price 22.08 yuan, five-day moving average 20.18 yuan, daily turnover rate 3.60% [1] - Tianwo Technology (Code: 002564): Latest price 9.02 yuan, five-day moving average 8.34 yuan, daily turnover rate 5.08% [1]

Core Viewpoint - The article highlights a significant surge in the innovative drug sector, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, which could lead to a total transaction value of up to $11.4 billion (approximately 81.2 billion RMB) [3][5]. Group 1: Market Performance - On October 22, A-shares and Hong Kong stocks related to innovative drugs experienced a strong rally, with several stocks like Innovent Biologics and Haisco Pharmaceutical hitting the daily limit [4]. - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [6]. Group 2: Strategic Collaboration - Innovent Biologics announced a global strategic partnership with Takeda to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [4][6]. - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with Takeda leading the global development and commercialization efforts outside of Greater China and the U.S. [4][5]. Group 3: Financial Implications - Innovent Biologics will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and could earn up to $10.2 billion in potential milestone payments [5]. - The partnership is expected to significantly enhance Takeda's oncology pipeline, which has faced challenges in recent years [6]. Group 4: Industry Trends - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [7]. - The fourth quarter is anticipated to see an acceleration in business development (BD) activities, with major pharmaceutical companies likely to allocate their annual budgets during this period [8].

Core Viewpoint - The pharmaceutical sector has experienced significant stock price increases, with Hendi Pharmaceutical reaching a 20% limit-up, and several other companies also showing substantial gains [1] Group 1: Company Performance - Hendi Pharmaceutical's stock surged by 20%, hitting the daily limit [1] - Duori Pharmaceutical's stock rose by over 13% [1] - Other companies such as Guangji Pharmaceutical, Te Yi Pharmaceutical, Hasan Lian, and Chenxin Pharmaceutical also reached their daily limit [1]

Core Viewpoint - The innovative drug sector is experiencing a significant boost, driven by a strategic collaboration between Innovent Biologics and Takeda Pharmaceutical, with a total deal value potentially reaching $11.4 billion (approximately 81.2 billion RMB) [1][3]. Group 1: Market Reaction - On October 22, A-shares and Hong Kong stocks related to innovative drugs surged, with companies like Angli康, 哈三联, and 亚太药业 hitting the daily limit, while药捷安康 saw an increase of over 25% [1][2]. - The biopharmaceutical sector in Hong Kong also experienced substantial gains, with notable increases in stocks such as 轩竹生物 and 信达生物 [2]. Group 2: Strategic Collaboration Details - The collaboration between 信达生物 and 武田制药 aims to accelerate the development of next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, including late-stage candidates IBI363 and IBI343, as well as an early-stage project IBI3001 [2][3]. - 信达生物 will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million, and has the potential to earn up to $10.2 billion in milestone payments [3]. Group 3: Market Trends and Future Outlook - The global oncology drug market has surpassed $200 billion, with the expiration of PD-1 patents creating new competitive opportunities [4]. - The trend of Chinese innovative drugs entering international markets continues, with contract values exceeding $100 billion in the first three quarters of the year, marking a 170% year-on-year increase [5][6]. - The fourth quarter is expected to see an acceleration in business development (BD) activities, as large international pharmaceutical companies typically allocate their annual budgets during this period [6]. Group 4: Investment Sentiment - Analysts suggest that the current environment is favorable for innovative biotech companies, with increased liquidity and risk appetite in the Hong Kong market [7]. - The focus on innovative drug companies is expected to grow as their core pipelines are validated, while second-tier pipelines are approaching proof-of-concept data [7].

Core Viewpoint - The innovative drug concept is gaining strength in the market, with notable stocks experiencing significant increases, indicating a positive trend in the pharmaceutical sector [1] Group 1: Stock Performance - Harbin Sanlian and Anglikang both reached the daily limit increase, reflecting strong investor interest [1] - Other companies such as Shutaishen, Asia-Pacific Pharmaceutical, Duori Pharmaceutical, Yipinhong, Shanghai Yizhong, and Jinshiyao also saw price increases, contributing to the overall positive sentiment in the sector [1]